section name header

Pronunciation

ha-loe-PER-i-dole

Classifications

Therapeutic Classification: antipsychotics

Pharmacologic Classification: butyrophenones

Indications

BEERS REMS

Unlabeled Uses:

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed following PO/IM administration. Decanoate salt is slowly absorbed and has a long duration of action.

Distribution: Concentrates in liver.

Protein Binding: 92%.

Metabolism/Excretion: Mostly metabolized by the liver.

Half-life: 21–24 hr.

Time/Action Profile

(antipsychotic activity)

ROUTEONSETPEAKDURATION
PO2 hr2–6 hr8–12 hr
IM20–30 min30–45 min4–8 hr
IM (decanoate)3–9 daysunknown1 mo

†Effect may persist for several days.

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: hypotension, QT interval prolongation, tachycardia, TORSADES DE POINTES, ventricular arrhythmias.

Derm: diaphoresis, photosensitivity, rash.

EENT: blurred vision, dry eyes.

Endo: amenorrhea, galactorrhea, gynecomastia.

GI: constipation, dry mouth, anorexia, hepatitis, ileus.

GU: impotence, urinary retention.

Hemat: AGRANULOCYTOSIS, anemia, leukopenia, neutropenia.

Metab: weight gain.

Neuro: extrapyramidal reactions, confusion, drowsiness, restlessness, SEIZURES, tardive dyskinesia.

Resp: respiratory depression.
Misc: hypersensitivity reactions, NEUROLEPTIC MALIGNANT SYNDROME.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

see Calculator

Haloperidol

Haloperidol Decanoate

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Haldol, Haldol Decanoate